Objective:
To evaluate efficacy of IB1001 with respect to breakthrough bleeding during prophylaxis and with respect to control of hemorrhaging in prophylaxis and on-demand treatment regimens in previously treated patients (PTPs)…
An international group of pharmaceutical companies have joined an alliance, with the purpose of pooling their industry technologies and expertise to develop a plasma-derived therapy for treating COVID-19. Formed by CSL Behring, the alliance also…
The National Hemophilia Foundation (NHF) is seeking comments on draft ASH ISTH NHF WHF clinical practice guidelines on VWD Diagnosis & Management.TThe goal of this joint effort is to create and maintain state-of-the-art guidelines to…
Today, the FDA released several new guidance documents with permanent and temporary (during the COVID-19 emergency) changes to several policies related to blood and plasma donation. Our organizations represent end users of blood and blood…
The U.S. Food and Drug Administration (FDA) recently approved Sevenfact, a new recombinant factor VIIa therapy manufactured by the French biotechnology company Laboratoire Francais du Fractionnement et des Biotechnologies (LFB). The FDA approval is…
The National Hemophilia Foundation is monitoring the availability of access to hemophilia treatment centers (HTCs) during the COVID-19 pandemic. Our HTC network is working to provide care during this time when many hospitals are currently…
Supplemental MASAC Statement Regarding Home Delivery and Refill Under State of Emergency Declaration
Patients on home therapy receive regular shipments of clotting factor concentrate (CFC) or non-factor replacement therapy (e.g., emicizumab-kxwh) from their pharmacy providers, often on a monthly basis or as home supplies are depleted. Having an…
Fill out my Wufoo form!
The National Hemophilia Foundation’s (NHF’s) Medical and Scientific Advisory Council (MASAC) issued four new documents, which were adopted by NHF’s Board of Directors on February 28, 2020.
MASAC Document #258, which replaces…